genetics eco

Nexalife

Pharmaceuticals
trending_up Nasdaq: NEXA

Investing in the Future of Health

Nexalife is committed to delivering long-term value to our shareholders through disciplined capital allocation and groundbreaking scientific innovation.

Current Price
$142.85 arrow_upward 1.2%
Market Cap
$14.2B
Dividend Yield
1.85%
Vol (Avg)
2.1M

NEXA Performance

11:30 AM
$142.10

Financial Results

Access our latest earnings reports and financial statements.

View All Filings arrow_forward
description
LATEST ANNUAL

Annual Report 2023

Published March 15, 2024

picture_as_pdf Download PDF download html Interactive Report open_in_new
analytics
QUARTERLY

Q3 2023 Earnings

Published October 24, 2023

picture_as_pdf Earnings Release download podcasts Webcast Replay play_circle
pie_chart
ARCHIVE

Q2 2023 Earnings

Published July 20, 2023

picture_as_pdf Earnings Release download slideshow Presentation Deck download

Corporate Governance

Nexalife maintains the highest standards of integrity and oversight, led by a diverse and experienced Board of Directors.

Governance Documents

Dr. Eleanor Vance

Chair of the Board

Former CEO of BioGenetics Inc, with 30+ years in pharmaceutical leadership.

James Sterling

Chief Executive Officer

Driving Nexalife's strategic vision towards precision medicine solutions.

verified_user

Ethical Standards

We are committed to transparency, compliance, and ethical conduct in all our operations.

Read Code of Conduct